UBS Group’s PharMerica Corporation PMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-529,482
| Closed | -$15.5M | – | 8376 |
|
|
2017
Q3 | $15.5M | Buy |
529,482
+431,618
| +441% | +$12.1M | 0.01% | 1288 |
|
|
2017
Q2 | $2.57M | Sell |
97,864
-659
| -0.7% | -$16.2K | ﹤0.01% | 2771 |
|
|
2017
Q1 | $2.31M | Sell |
98,523
-3,519
| -3% | -$86.8K | ﹤0.01% | 2827 |
|
|
2016
Q4 | $2.57M | Buy |
102,042
+3,604
| +4% | +$91K | ﹤0.01% | 2686 |
|
|
2016
Q3 | $2.76M | Buy |
98,438
+12,376
| +14% | +$317K | ﹤0.01% | 2549 |
|
|
2016
Q2 | $2.12M | Buy |
86,062
+3,384
| +4% | +$84K | ﹤0.01% | 2734 |
|
|
2016
Q1 | $1.83M | Buy |
82,678
+4,407
| +6% | +$117K | ﹤0.01% | 2757 |
|
|
2015
Q4 | $2.74M | Buy |
78,271
+1,616
| +2% | +$50.6K | ﹤0.01% | 2509 |
|
|
2015
Q3 | $2.18M | Buy |
76,655
+14,480
| +23% | +$486K | ﹤0.01% | 2665 |
|
|
2015
Q2 | $2.07M | Buy |
62,175
+2,936
| +5% | +$90.1K | ﹤0.01% | 2945 |
|
|
2015
Q1 | $1.67M | Sell |
59,239
-210,470
| -78% | -$5.23M | ﹤0.01% | 3103 |
|
|
2014
Q4 | $5.59M | Buy |
+269,709
| New | +$6.4M | ﹤0.01% | 2007 |
|
UBS Group's PMC Position: Q4 2017 in Review
UBS Group sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 529,482 shares — an estimated $15.5M sold.
UBS Group first reported a position in PMC in Q4 2014 and held it in 12 quarters. The position peaked at $15.5M in Q3 2017. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.
- UBS Group reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
- UBS Group sold 529,482 PharMerica Corporation shares in Q4 2017, an estimated $15.5M.
- UBS Group first reported a position in PharMerica Corporation in Q4 2014 and held it in 12 quarters.
- UBS Group's PharMerica Corporation position peaked at $15.5M in Q3 2017.
- 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.
Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.